Allergan Wins Right to Market Anti-Acne Drug

Allergan Inc. has won U.S. and Canadian marketing rights to an anti-acne medication sold in Europe by Schering AG of Germany, the company said Monday.

Herbert Laboratories, the skin care division of Allergan, will begin clinical studies on the topical compound, azelaic acid, and seek FDA approval, a process expected to take at least three years, said Allergan spokesman Jeff D’Eliscu.

Schering has been marketing azelaic acid as Skinoren cream in Europe, the company said.